Orchard Therapeutics PLC $ 6.99 0.14 (2.04%)
Volume:
503,223
Avg Vol (1m):
3,082,026
Market Cap $:
854.28 Mil
Enterprise Value $:
711.06 Mil
PE Ratio:
0.00
PB Ratio:
3.29
Financial Strength | 4/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 3.46 | ||
| Equity-to-Asset | 0.69 | ||
| Debt-to-Equity | 0.28 | ||
| Debt-to-EBITDA | -0.34 | ||
| Altman Z-Score | 1.79 | ||
| WACC vs ROIC | |||
Profitability Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -5239.22 | ||
| Net Margin % | -5134.01 | ||
| ROE % | -61.22 | ||
| ROA % | -45.96 | ||
| ROC (Joel Greenblatt) % | -695.38 | ||
| 3-Year EBITDA Growth Rate | 1.2 | ||
| 3-Year EPS without NRI Growth Rate | 13.4 |
ORTX
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 3.29 | ||
| PS Ratio | 219.06 | ||
| EV-to-EBIT | -4.16 | ||
| EV-to-EBITDA | -4.21 | ||
| EV-to-Revenue | 222.89 | ||
| Current Ratio | 5.74 | ||
| Quick Ratio | 5.74 | ||
| Days Sales Outstanding | 364.2 | ||
| Days Payable | 2039.34 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -112.5 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 3.31 | ||
| Earnings Yield (Greenblatt) % | -24.01 |